Lakewood-Amedex Biotherapeutics Inc. - What You Need to Know

Thinking about investing in Lakewood-Amedex Biotherapeutics? Before you put your money down, let’s break down what this company actually does in plain English.

Here is a guide to help you decide if this fits your portfolio.

1. What does this company do?

Lakewood-Amedex is a biotech company currently in the research phase. They are developing a new class of drugs called Bisphosphocins®. These are designed to kill "superbugs"—bacteria that resist traditional antibiotics—by attacking the bacteria’s outer layer.

Their main project, Nu-3, is a gel for treating infected diabetic foot ulcers. Because they are still in the testing phase, they do not sell any products yet. They have not received approval from the FDA or any other health agency to sell their drugs.

2. How are they going public?

They are using a "Direct Listing" on the Nasdaq under the symbol "LABT."

• What this means: Unlike a traditional IPO, the company is not issuing new shares to raise money. Instead, current shareholders are simply registering their existing shares to sell them directly to the public.
• The Catch: There is no traditional underwriting process to support the stock price. Without this support, and with no "lock-up" period to prevent early investors from selling, the stock price may swing wildly or drop quickly once trading begins.

3. The Financial Reality

• Zero Revenue: As of September 30, 2025, the company has made $0 in sales since it started.
• High Costs: They lost about $3.1 million in the first nine months of 2025. These costs come from research and running the business.
• Tight Cash: As of September 30, 2025, they had about $658,000 in cash. Meanwhile, they owe over $2.2 million in debts.
• The "Dilution" Warning: The company admits it does not have enough cash to last the next 12 months. They will need to raise more money soon. If they issue more shares to raise this cash, your ownership percentage will shrink, which could lower the value of your investment.

4. What are the main risks?

• The "Trial Trap": Many of their trials are "open-label," meaning everyone knows who is getting the drug. This can create bias, making the results less reliable than the strict, blind studies the FDA requires for approval.
• Safety Hurdles: If their drugs show unexpected side effects, the FDA could pause or stop their research entirely. This would likely end the company’s chances of success.
• Logistics: Their products may require strict temperature control. If the supply chain fails, the drugs could become ineffective or fail to meet safety rules.
• Lack of Experience: The company has never sold a drug before. They lack the sales and marketing teams needed to bring a product to market. They must either build these teams from scratch or find a partner, neither of which is guaranteed.

5. The Bottom Line

This is a high-stakes bet on scientific success. You are betting that their technology will pass strict government tests and become a real treatment. With no sales, more debt than cash, and the high risks of drug development, this is a very speculative investment. It is not a "set it and forget it" stock, and you could lose your entire investment.

How to make your final decision: If you are still interested, don't stop here. Before you buy, go to the SEC’s EDGAR database and search for "Lakewood-Amedex." Read the "Risk Factors" section of their latest prospectus. It is long, but it contains the most honest look at exactly how they could fail. If you aren't comfortable with those risks, it’s perfectly okay to sit this one out.

Disclaimer: I am an AI, not a financial advisor. Biotech stocks are extremely volatile. Never invest money you cannot afford to lose.